Abdelwahab Omri Selected Research

Abdelwahab Omri Research Topics

Disease

19	Infections 01/2022 - 11/2002
9	Neoplasms (Cancer) 01/2022 - 12/2010
7	Cystic Fibrosis (Mucoviscidosis) 04/2021 - 02/2005
5	Dehydration (Water Stress) 03/2015 - 01/2006
4	Communicable Diseases (Infectious Diseases) 01/2022 - 11/2013
3	Acquired Immunodeficiency Syndrome (AIDS) 07/2021 - 01/2019
3	Pulmonary Edema 11/2008 - 01/2002
3	Body Weight (Weight, Body) 11/2008 - 11/2002
3	Lung Injury 11/2008 - 01/2002
2	COVID-19 01/2022 - 01/2020
2	Wounds and Injuries (Trauma) 11/2021 - 01/2007
2	Sepsis (Septicemia) 11/2019 - 06/2009
2	HIV Infections (HIV Infection) 01/2019 - 01/2017
2	Pseudomonas Infections 03/2015 - 01/2013
2	Necrosis 05/2013 - 01/2007
1	Colorectal Neoplasms (Colorectal Cancer) 01/2022
1	Wound Infection (Wound Infections) 11/2021
1	Respiratory Tract Infections (Respiratory Tract Infection) 10/2021
1	Retinopathy of Prematurity (Retrolental Fibroplasia) 08/2021
1	Bronchopulmonary Dysplasia 08/2021
1	Hemorrhage 08/2021
1	Epilepsy (Aura) 01/2021
1	Peritonitis 11/2019
1	Extensively Drug-Resistant Tuberculosis 01/2019
1	Atherosclerosis 01/2018
1	Bacteremia 01/2016
1	Pneumonia (Pneumonitis) 03/2014
1	Inflammation (Inflammations) 11/2011
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2010
1	Breast Neoplasms (Breast Cancer) 12/2010
1	Anaphylaxis (Anaphylactic Shock) 12/2010

Drug/Important Bio-Agent (IBA)

14	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 12/2004
11	Pharmaceutical PreparationsIBA 01/2022 - 02/2005
11	Liposomes (Liposome)IBA 01/2017 - 11/2002
4	Tobramycin (Nebcin)FDA LinkGeneric 11/2013 - 01/2006
3	Vancomycin FDA LinkGeneric 11/2019 - 09/2012
3	Peroxidase (Myeloperoxidase)IBA 11/2011 - 01/2002
3	Polymyxin B (Aerosporin)FDA LinkGeneric 05/2009 - 11/2002
3	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 11/2008 - 01/2002
3	Gentamicins (Gentamicin)FDA LinkGeneric 01/2006 - 12/2004
2	Anti-Infective Agents (Microbicides)IBA 01/2022 - 10/2021
2	Drug CarriersIBA 11/2021 - 01/2018
2	Immunologic Factors (Immunomodulators)IBA 07/2021 - 01/2017
2	GoldIBA 07/2021 - 01/2021
2	AminoglycosidesIBA 04/2021 - 01/2006
2	MacrolidesIBA 04/2021 - 01/2006
2	Reverse Transcriptase InhibitorsIBA 01/2017 - 01/2017
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2011 - 01/2007
2	Glutathione (Reduced Glutathione)IBA 11/2011 - 01/2002
2	dimyristoylphosphatidylglycerol (DMPG)IBA 12/2010 - 11/2002
2	Dimyristoylphosphatidylcholine (DMPC)IBA 12/2010 - 11/2002
2	N-acetylcysteine lysinateIBA 11/2008 - 01/2007
2	Acetylcysteine (Siran)FDA LinkGeneric 11/2008 - 01/2007
1	Volatile Oils (Essential Oils)IBA 01/2022
1	LigandsIBA 01/2022
1	ProdrugsIBA 01/2022
1	Polysaccharides (Glycans)IBA 01/2022
1	CelluloseIBA 11/2021
1	Biocompatible Materials (Biomaterials)IBA 11/2021
1	VitaminsIBA 08/2021
1	AntigensIBA 07/2021
1	ChitosanIBA 01/2021
1	Antineoplastic Agents (Antineoplastics)IBA 01/2021
1	Dosage Forms (Dosage Form)IBA 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	SilverIBA 01/2021
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 01/2021
1	Anti-Retroviral Agents (Antiretroviral Agents)IBA 01/2019
1	PolymersIBA 01/2017
1	NucleosidesIBA 01/2017
1	Dendrimers (Dendrons)IBA 01/2017
1	MicellesIBA 01/2017
1	efavirenz (Sustiva)FDA Link 01/2017
1	VaccinesIBA 06/2015
1	Azithromycin (Zithromax)FDA LinkGeneric 03/2015
1	Interleukin-8 (Interleukin 8)IBA 03/2014
1	Clarithromycin (Biaxin)FDA LinkGeneric 06/2013
1	Acetaminophen (Paracetamol)FDA LinkGeneric 05/2013
1	1,2-ethanedithiol (ethanedithiol)IBA 01/2013
1	AgarIBA 01/2013
1	Virulence Factors (Pathogenicity Factors)IBA 01/2013
1	chloramineIBA 11/2011
1	3-nitrotyrosineIBA 11/2011
1	Alanine (L-Alanine)FDA Link 11/2011
1	Proteins (Proteins, Gene)FDA Link 11/2011
1	Aspartic Acid (Aspartate)FDA Link 11/2011
1	AntioxidantsIBA 11/2011
1	Transaminases (Aminotransferases)IBA 11/2011
1	RicinIBA 11/2011
1	Oxidants (Oxidizing Agents)IBA 11/2011
1	cremophor ELIBA 12/2010
1	Ethanol (Ethyl Alcohol)IBA 12/2010

Therapy/Procedure

8	Therapeutics 01/2022 - 06/2009
5	Fluid Therapy (Oral Rehydration Therapy) 03/2015 - 01/2006
3	Immunotherapy 07/2021 - 01/2017
2	Precision Medicine 01/2021 - 01/2018
1	Oral Administration 10/2021
1	Nanospheres 07/2021
1	Highly Active Antiretroviral Therapy (HAART) 01/2020
1	Intraperitoneal Injections 09/2012